Psychiatric Polyclinic: A Cross Sectional Study in the Context of Schizophrenia Treatment

Year 2018, , 142 - 148, 13.11.2018

Tacettin Kuru , M.hakan Türkçapar

https://doi.org/10.30565/medalanya.419653

Abstract

Aim:  The aim of this
study was to investigate the sociodemographic characteristics of patients who
applied to the Psychiatry Outpatient Clinic of Education and Research Hospital
and to evaluate the treatment and follow-up results of patients diagnosed with
schizophrenia.

Material and Methods: 
2707 applications whiche were received to the psychiatric outpatient
clinic were evaluated . Also the treatments of 
schizopherina patients in polyclinic were analysed.

Results:  During the
study period, 2707 applications were made to the psychiatry polyclinic. 649
(24%) of the patients were diagnosed with schizophrenia and other psychotic
disorders. 506 (18.7%) of the patiens were diagnosed with depressive disorders.
389 (14.4%) of the patients were diagnosed with anxiety disorders and 117
(4.3%) of the patients were diagnosed with bipolar. 347 (62%) of the
schizophrenic patients were on a single medication. 287 (51.3%) of these
patients were taking atypical antipsychotics and 60 (10.7%) of them were taking
typical antipsychotics. 205 (36.6%) of all patients were taking combined
antipsychotic medication. We found that 77.5% of patients with schizophrenia
were prescribed atypical antipsychotics alone or in combination.

Conclusion:  Psychiatric
polyclinics are the most important fields of study for psychiatric treatment.
Evaluation of chronic diseases which cause significant loss of competence in
disease specialized rehabilitation units will provide more effective use of
psychiatric polyclinics in both service and research areas. For schizophrenia
treatment, we found results that were in accordance with the literature but not
with the treatment protocols. Holistic treatment approach, including
non-pharmacological treatments for schizophrenia should be pushed forward.

Keywords

Outpatients, Schizophrenia, Prescription Tendencies

Psikiyatri Polikliniği: Şizofreni Tedavisi Bağlamında Kesitsel Bir Çalışma

Abstract

Amaç: Bu çalışmanın amacı; Eğitim ve Araştırma Hastanesi
Psikiatri Polikliniğine başvuran hastaların sosyodemografik özelliklerini
araştırmak ve Şizofreni tanısı alan hastaların tedavi ve takip sonuçlarını
değerlendirmektir.

Gereç ve Yöntem: Psikiyatri polikliniğine yapılan
2707  başvuru değerlendirildi. Ayrıca
şizofreni hastalarına poliklinik şartlarında uygulanan tedaviler incelendi.

Bulgular: Araştırma süresince psikiyatri polikliniğine toplam
2707 başvuru yapılmıştır. Çalışmaya alınan hastaların 649’u (%24) şizofreni ve
diğer psikotik bozukluklar, 506’sı (%18,7) depresif bozukluklar, 389’u (%14,4)
anksiyete bozuklukları, 117’si (%4,3) bipolar bozukluklar tanısı almıştı.
Şizofreni hastalarının 347’si (%62) tek ilaç kullanıyordu. Bu hastaların 287’si
(%51,3) atipik antipsikotik, 60’ı (%10,7)ise tipik antipsikotik almaktaydı.
Hastaların 205’i (%36,6) kombine antipsikotik kullanmaktaydı. Çalışmamızda
şizofreni hastalarının %77,5’ine, tek başına veya kombinasyon şeklinde atipik
antipsikotik reçetelendiğini saptadık.

Sonuç: Psikiyatri poliklinikleri, psikiyatrik tedavinin en önemli
çalışma alanlarıdır. Belirgin yeti yıkımına yol açan kronik hastalıkların,
hastalığa özelleşmiş rehabilitasyon alanlarında değerlendirilmesi, psikiyatri
polikliniklerinin hem hizmet hem de araştırma alanlarında daha etkin
kullanımını sağlayacaktır. Şizofreni tedavisinde, literatüre uygun ancak tedavi
protokollerine uymayan sonuçlar saptadık. Şizofreni tedavisinde, ilaç dışı
tedavileri de içeren bütüncül tedavi yaklaşımına daha fazla dikkat
çekilmelidir.

Keywords

Poliklinik hastaları, şizofreni, ilaç reçeteleme eğilimleri

References

• 1. Vos T. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2163-2196.
• 2. N, Kılıç C, Ulusoy M, Keçeci M, Şimşek Z. T.C. Sağlık Bakanlığı Türkiye Ruh Sağlığı Profili Araştırması, Ana Rapor 1998; 77-95.
• 3. Rothbard AB, Kuno E, Foley K. Trends in the Rate and Type of Antipsychotic Medications Prescribed to Persons With Schizophrenia. Schizophr Bull 2003; 29:531-540.
• 4. Martin BC, Miller LS, Kotzan JA. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts. Schizophr Res. 2001;47:281- 292.
• 5. Frank RG, Conti RM, Goldman HH. Mental Health Policy and Psychotropic Drugs. Milbank Q.2005; 83:271–298.
• 6. Hermann RC, Yang D, Ettner SL, Marcus SC, Yoon C, Abraham M. Prescription of Antipsychotic Drugs by Office-Based Physicians in the United States, 1989-1997. Psychiatr Serv. 2002; 53:425-430.
• 7. Aparasu RR, Bhatara V, Gupta S. US. national trends in the use of antipsychotics during office visits, 1998–2002. Ann Clin Psychiatry. 2005;17:147-152.
• 8. Santamaria B, Perez M, Montero D, Madurga M, Abajo FJ. Use of antipsychotic agents in Spain through 1985-2000. Eur Psychiatry 2002;17:471-476.
• 9. Alptekin K, Ulas H, Akdede BB ve ark. (2009) Prevalence and risk factors of psychotic symptoms: in the city of Izmir, Turkey. Soc Psychiatry Psychiatr Epidemiol 44: 905-10.
• 10. Denckner S: The need for long-term neuroleptic treatment in schizophrenia. Acta Psychiatr Scand Suppl 1981; 291:29–43
• 11. The expert consensus guideline series: treatment of schizophrenia1999. J Clin Psychiatry 1999; 60(suppl 11): 3–80.
• 12. Lehman AF, Steinwachs DM (Co-Investigators of the PORT Project): Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1–10
• 13. Wang PS, West JC, Tanielian T and Pincus HA. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000;26: 451-457
• 14. Leslie D.L , Rosenheck R. A. Am J Psychiatry 2002: Sept; 159:9,
• 16. Geddes J. Generating evidence to inform policy and practice: the example of the second generation “atypical” antipsychotics. Schizophr Bull 2003;29: 105–114
• 17. Mond J,Morice R,Owen C,Korten A . Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003; 37: 55–61
• 18. Santamaria B, Perez M, Montero D, Madurga M, de Abajo FJ. Use of antipsychotic agents in Spain through 1985–2000. Eur Psychiatry 2002; 17: 471–476
• 19. Kane Jm, Woemer m, Borenstein M. İntegrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull1986;22: 254-258
• 20. Marder SR, May PR. Benefits and limitations of neuroleptics-and other forms of treatment in schizophrenia. Am J Psychother 1986;40: 357-369
• 21. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995;21: 567-577
• 22. Hogarty GE, Schooler NR, Ulrich R,Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analysis of a controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry 1979; 36: 1283–1294
• 23. Fayek M, Flowers C, Signorelli D and Simpson G. Psychopharmacology: Underuse of Evidence-Based Treatments in Psychiatry . Psychiatr Serv 2003; November: 54: 1453-1456
• 24. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49: 196-201
• 25.Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23: 637-651
• 26. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J,Weiden PJ. Predicting medication noncompliance after hospitol discharce among patients with schizophrenia. Psychiatr Serv 2000;51: 216-222
• 27. Ruscher SM, de Wit R, Mazmanian D. Psychiatric patients’ attitudes about medication and factors affecting noncompliance. Psychiatr Serv 1997;48: 82-85
• 28. Miller AL, Chiles JA, Chiles JK, ve ark. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999;60: 649-657
• 29. İto H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrist’s perceptions of antipsychotic drug prescription .. Br J Psychiatry 2005. 187; 243-247
• 30. Göka E ve ark. Ülkemizdeki ruh sağlığı hizmetlerinin örgütlenme sorunları ve bazı öneriler. T Klin Psikiyatri 2002, 3: 80-92